| Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ... The lancet oncology 21 (5), 645-654, 2020 | 372 | 2020 |
| Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer A Fontana, L Galli, A Fioravanti, P Orlandi, C Galli, L Landi, S Bursi, ... Clinical Cancer Research 15 (15), 4954-4962, 2009 | 106 | 2009 |
| Clinical and comparative utility of afatinib in non-small cell lung cancer M D’Arcangelo, FR Hirsch Biologics: Targets and Therapy, 183-192, 2014 | 45 | 2014 |
| K‐Ras mutations in non‐small‐cell lung cancer: prognostic and predictive value M D’arcangelo, F Cappuzzo International Scholarly Research Notices 2012 (1), 837306, 2012 | 44 | 2012 |
| Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer M D’Arcangelo, F Cappuzzo Biologics: Targets and Therapy, 61-68, 2013 | 42 | 2013 |
| Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial MC Piccirillo, L Bonanno, MC Garassino, G Esposito, C Dazzi, L Cavanna, ... Journal of Thoracic Oncology 17 (9), 1086-1097, 2022 | 40 | 2022 |
| RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer S Rao, V Sigl, RA Wimmer, M Novatchkova, A Jais, G Wagner, ... Genes & Development 31 (20), 2099-2112, 2017 | 39 | 2017 |
| Rare mutations in non-small-cell lung cancer M D’Arcangelo, A D’Incecco, F Cappuzzo Future oncology 9 (5), 699-711, 2013 | 38 | 2013 |
| Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer A Fontana, G Bocci, L Galli, M D'Arcangelo, L Derosa, A Fioravanti, ... Journal of the American Geriatrics Society 58 (5), 986-988, 2010 | 34 | 2010 |
| Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment V Subbiah, L Paz-Ares, B Besse, V Moreno, S Peters, MA Sala, ... Lung Cancer 150, 90-96, 2020 | 31 | 2020 |
| Erlotinib in the first-line treatment of non-small-cell lung cancer M D’Arcangelo, F Cappuzzo Expert review of anticancer therapy 13 (5), 523-533, 2013 | 28 | 2013 |
| Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC) S Vecchiarelli, F Passiglia, A D’Incecco, M Gallo, A De Luca, E Rossi, ... Oncotarget 9 (25), 17554, 2018 | 26 | 2018 |
| Prognostic value of p16 protein in patients with surgically treated non-small cell lung cancer; relationship with Ki-67 and PD-L1 A Pezzuto, F Cappuzzo, M D'ARCANGELO, M Ciccozzi, L Navarini, ... Anticancer Research 40 (2), 983-990, 2020 | 20 | 2020 |
| The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer M D’Arcangelo, MW Wynes, FR Hirsch Current opinion in oncology 25 (2), 121-129, 2013 | 19 | 2013 |
| Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer M D’Arcangelo, A D’Incecco, C Ligorio, S Damiani, M Puccetti, ... Oncotarget 10 (5), 561, 2019 | 17 | 2019 |
| The role of PARP in DNA repair and its therapeutic exploitation M D’Arcangelo, Y Drew, R Plummer DNA Repair in Cancer Therapy, 115-134, 2016 | 16 | 2016 |
| Cancer stem cells sensitivity assay (STELLA) in patients with advanced lung and colorectal cancer: a feasibility study M D’Arcangelo, M Todaro, J Salvini, A Benfante, ML Colorito, A D’Incecco, ... PLoS One 10 (5), e0125037, 2015 | 15 | 2015 |
| Prevalence and prognostic significance of sodium-dependent phosphate transporter 2b (NaPi2b) protein expression in non-small cell lung cancer (NSCLC) M D'Arcangelo, OT Brustugun, Y Xiao, Y Choi, C Behrens, LM Solis, ... Annals of Oncology 25, iv66, 2014 | 15 | 2014 |
| LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial MJ Ahn, SW Kim, EC Costa, LM Rodríguez, J Oliveira, MAI Molla, ... Annals of Oncology 33, S1423, 2022 | 12 | 2022 |
| P2. 01-15 phase II single arm study of CABozantinib in non-small cell lung cancer patients with MET deregulation (CABinMET) M D'Arcangelo, D Tassinari, F De Marinis, A Delmonte, D Galetta, ... Journal of Thoracic Oncology 14 (10), S644, 2019 | 12 | 2019 |
